FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387440061> ?p ?o ?g. }

• W4387440061 abstract "Immune checkpoint inhibitors are increasingly important in the treatment algorithm for locally advanced and metastatic bladder cancer. Numerous ongoing studies are investigating these agents as first- and second-line therapies, both alone and in combination with chemotherapy or in a maintenance therapy setting.To assess the effects of immune checkpoint inhibitors compared to chemotherapy as first- and second-line treatment of advanced or metastatic urothelial carcinoma.We performed a comprehensive search including the Cochrane Library, MEDLINE, Embase, three other databases, several trial registers, other sources of gray literature, and conference proceedings, with no restrictions on language of publication. We limited the search period to run from 2000 until August 2022.We included randomized controlled trials (RCTs) using immunotherapy versus chemotherapy and would have considered non-randomized trials in the absence of randomized trial data. Participants had locally advanced inoperable (cT4b or N+, or both) or metastatic (M1) (or both) urothelial carcinoma of the bladder or upper urinary tract. We excluded studies of people in whom immunotherapy was used in combination with chemotherapy or in a surveillance setting.Two review authors independently classified studies for inclusion and abstracted data from included studies. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of evidence on a per-outcome basis.We included five RCTs and identified seven single-armed studies. The RCTs included 3572 participants comparing immunotherapy versus chemotherapy for the treatment of locally advanced and metastatic bladder cancer. First-line therapy Immunotherapy probably has little to no effect on the risk of death from any cause when used as first-line therapy compared to chemotherapy (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.87 to 1.07; I2 = 0%; 3 studies, 2068 participants; moderate-certainty evidence). This corresponds to 750 deaths per 1000 participants with chemotherapy and 11 fewer (45 fewer to 26 more) deaths per 1000 participants with immunotherapy at 36 months. Immunotherapy probably has little to no effect on health-related quality of life (mean difference (MD) 4.10, 95% CI 3.83 to 4.37; 1 study, 393 participants; moderate-certainty evidence), when assuming a minimal clinically important difference (MCID) of at least 6 points (using the Functional Assessment of Cancer Therapy - Bladder [FACT-BL] tool; scale 0 to 156 with higher scores representing better quality of life). Immunotherapy probably reduces adverse events grade 3 to 5 (RR 0.47, 95% CI 0.29 to 0.75; I2 = 97%; 3 studies, 2046 participants; moderate-certainty evidence). This corresponds to 908 grade 3 to 5 adverse events per 1000 participants with chemotherapy, with 481 fewer (644 fewer to 227 fewer) grade 3 to 5 adverse events per 1000 participants with immunotherapy. We found no evidence for the outcome time to death from bladder cancer. Immunotherapy probably increases the risk of time to disease progression (HR 1.33, 95% CI 1.17 to 1.50; I2 = 0%; 2 studies, 1349 participants; moderate-certainty evidence). This corresponds to 660 events per 1000 participants with chemotherapy and 102 more (57 more to 152 more) events per 1000 participants with immunotherapy at 36 months. Immunotherapy may reduce discontinuations due to adverse effects (RR 0.47, 95% CI 0.20 to 1.10; I2 = 94%; 3 studies, 2046 participants; low-certainty evidence). This corresponds to 338 discontinuations per 1000 participants with chemotherapy and 179 fewer (271 fewer to 34 more) discontinuations per 1000 participants with immunotherapy. Second-line therapy Immunotherapy may reduce the risk of death from any cause when used as second-line therapy (HR 0.72, 95% CI 0.63 to 0.81; I2 = 0%; 2 studies, 1473 participants; low-certainty evidence). This corresponds to 920 deaths per 1000 participants with chemotherapy (vinflunine, paclitaxel, docetaxel) and 59 fewer (95 fewer to 28 fewer) deaths per 1000 participants with immunotherapy at 36 months. Immunotherapy may have little to no effect on health-related quality of life when compared to chemotherapy (MD 4.82, 95% CI -3.11 to 12.75; I2 = 85%; 2 studies, 727 participants; low-certainty evidence), assuming an MCID of at least 10 points (using the EORTC QLQ tool; scale 0 to 100 with higher scores representing better quality of life). Immunotherapy may reduce adverse events grade 3 to 5 in participants undergoing second-line therapy (RR 0.89, 95% CI 0.81 to 0.97; I2 = 9%; 2 studies, 1423 participants; low-certainty evidence). This corresponds to 630 grade 3 to 5 adverse events per 1000 participants with chemotherapy and 76 fewer (126 fewer to 25 fewer) grade 3 to 5 adverse events per 1000 participants with immunotherapy. We found no evidence for the outcome of time to death from bladder cancer. We are very uncertain if immunotherapy reduces the risk of disease progression (HR 0.99, 95% CI 0.84 to 1.16; I2 = 0%; 2 studies, 1473 participants; very low-certainty evidence). Immunotherapy may reduce discontinuations due to adverse events in participants undergoing second-line therapy (RR 0.35, 95% CI 0.17 to 0.72; I2 = 69%; 2 studies, 1473 participants; low-certainty evidence). This corresponds to 110 discontinuations per 1000 participants with chemotherapy and 72 fewer (91 fewer to 31 fewer) discontinuations per 1000 participants with immunotherapy.Compared to chemotherapy, immunotherapy for treating advanced or metastatic urothelial carcinoma probably has little to no effect on the risk of death from any cause when used as first-line therapy. Still, it may reduce the risk of death from any cause when used as second-line therapy. Health-related quality of life for participants receiving first- and second-line therapy does not appear to be affected by immunotherapy. Immunotherapy probably reduces or may reduce adverse events grade 3 to 5 when used as first- and second-line therapy, respectively." @default.
• W4387440061 created "2023-10-10" @default.
• W4387440061 creator A5001861927 @default.
• W4387440061 creator A5013238443 @default.
• W4387440061 creator A5020779530 @default.
• W4387440061 creator A5028524700 @default.
• W4387440061 creator A5038376295 @default.
• W4387440061 creator A5067816501 @default.
• W4387440061 creator A5073558224 @default.
• W4387440061 date "2023-10-09" @default.
• W4387440061 modified "2023-10-18" @default.
• W4387440061 title "Immunotherapy for advanced or metastatic urothelial carcinoma" @default.
• W4387440061 cites W1857682357 @default.
• W4387440061 cites W1962829821 @default.
• W4387440061 cites W1971208896 @default.
• W4387440061 cites W1992070700 @default.
• W4387440061 cites W2004630197 @default.
• W4387440061 cites W2019607817 @default.
• W4387440061 cites W2063264144 @default.
• W4387440061 cites W2071183770 @default.
• W4387440061 cites W2084075250 @default.
• W4387440061 cites W2098028863 @default.
• W4387440061 cites W2101562875 @default.
• W4387440061 cites W2102116016 @default.
• W4387440061 cites W2103257412 @default.
• W4387440061 cites W2104675861 @default.
• W4387440061 cites W2108855090 @default.
• W4387440061 cites W2120955645 @default.
• W4387440061 cites W2125435699 @default.
• W4387440061 cites W2126930838 @default.
• W4387440061 cites W2134236426 @default.
• W4387440061 cites W2148562299 @default.
• W4387440061 cites W2152762320 @default.
• W4387440061 cites W2160795579 @default.
• W4387440061 cites W2162130153 @default.
• W4387440061 cites W2167571044 @default.
• W4387440061 cites W2168812605 @default.
• W4387440061 cites W2189590588 @default.
• W4387440061 cites W2289712604 @default.
• W4387440061 cites W2414977199 @default.
• W4387440061 cites W2436457051 @default.
• W4387440061 cites W2470163336 @default.
• W4387440061 cites W2478515289 @default.
• W4387440061 cites W2478608041 @default.
• W4387440061 cites W2487949013 @default.
• W4387440061 cites W2491789338 @default.
• W4387440061 cites W2519766257 @default.
• W4387440061 cites W2530516001 @default.
• W4387440061 cites W2559804019 @default.
• W4387440061 cites W2560322684 @default.
• W4387440061 cites W2567362164 @default.
• W4387440061 cites W2570159314 @default.
• W4387440061 cites W2582671354 @default.
• W4387440061 cites W2586210842 @default.
• W4387440061 cites W2587063754 @default.
• W4387440061 cites W2587799561 @default.
• W4387440061 cites W2587806815 @default.
• W4387440061 cites W2588211210 @default.
• W4387440061 cites W2588427383 @default.
• W4387440061 cites W2588916311 @default.
• W4387440061 cites W2591772299 @default.
• W4387440061 cites W2597811717 @default.
• W4387440061 cites W2597828919 @default.
• W4387440061 cites W2599150633 @default.
• W4387440061 cites W2599659630 @default.
• W4387440061 cites W2600033923 @default.
• W4387440061 cites W2601689261 @default.
• W4387440061 cites W2604441970 @default.
• W4387440061 cites W2615126323 @default.
• W4387440061 cites W2736085757 @default.
• W4387440061 cites W2752793362 @default.
• W4387440061 cites W2755371812 @default.
• W4387440061 cites W2759572614 @default.
• W4387440061 cites W2760661635 @default.
• W4387440061 cites W2760735711 @default.
• W4387440061 cites W2762013846 @default.
• W4387440061 cites W2762476265 @default.
• W4387440061 cites W2762723742 @default.
• W4387440061 cites W2762830460 @default.
• W4387440061 cites W2766262858 @default.
• W4387440061 cites W2768547622 @default.
• W4387440061 cites W2771737095 @default.
• W4387440061 cites W2777192533 @default.
• W4387440061 cites W2781097747 @default.
• W4387440061 cites W2783137027 @default.
• W4387440061 cites W2788898141 @default.
• W4387440061 cites W2793220344 @default.
• W4387440061 cites W2793511528 @default.
• W4387440061 cites W2794091331 @default.
• W4387440061 cites W2794297331 @default.
• W4387440061 cites W2794375875 @default.
• W4387440061 cites W2794976313 @default.
• W4387440061 cites W2864040241 @default.
• W4387440061 cites W2890138337 @default.
• W4387440061 cites W2890283163 @default.
• W4387440061 cites W2891431179 @default.
• W4387440061 cites W2891732223 @default.
• W4387440061 cites W2892218953 @default.
• W4387440061 cites W2895926103 @default.
• W4387440061 cites W2897581755 @default.

• next